ArticleBMC public health2021
Vaccination coverage estimates and utilization patterns of inactivated enterovirus 71 vaccine post vaccine introduction in Ningbo, China.
Article in BMC public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 25 citations in OpenAlex.
- Phase I, Single-Dose Study to Assess the Pharmacokinetics and Safety of Suramin in Healthy Chinese Volunteers.Drug design, development and therapy · 2023Trial
- Exploring the impact of reimbursement ratios on willingness to vaccinate: A mixed-effects modeling approach using panel data.Human vaccines & immunotherapeutics · 2026Article
- Real-world effectiveness of EV-A71 vaccine against encephalitis in children.Human vaccines & immunotherapeutics · 2026Article
- The gut virome and regulatory T cell axis in health and systemic disease.Microbiome research reports · 2026Review
- Enterovirus A71 priorities, challenges, and future opportunities in humoral immunity and vaccine development.NPJ vaccines · 2025Review
- Combined Antiviral and Cytoprotective Action of Rosmarinic Acid Against EV-A71 Infection: A Potential Therapeutic Strategy.Pathogens (Basel, Switzerland) · 2025Article
- Epidemiological characteristics of 5838 cases of enterovirus infection in children in Hangzhou from 2018 to 2023.Scientific reports · 2025Article
- Integrative scRNA-seq and transcriptomic analysis initially reveals monocyte/macrophage activation drives EV-A71-induced immune dysregulation and neural injury in severe HFMD.Frontiers in immunology · 2025Article
- Safety of an inactivated enterovirus 71 vaccine administered concurrently with other vaccines among infants aged 6-11 months: An observational study using active surveillance.Human vaccines & immunotherapeutics · 2024Observational
- Exploring the spatiotemporal effects of meteorological factors on hand, foot and mouth disease: a multiscale geographically and temporally weighted regression study.BMC public health · 2024Article
- Analysis of the Impact of Inactivated A71 Vaccine on the Incidence of Hand-Foot-Mouth Disease in Pudong New Area, Shanghai.Vaccines · 2024Article
- Spatiotemporal Changes and Influencing Factors of Hand, Foot, and Mouth Disease in Guangzhou, China, From 2013 to 2022: Retrospective Analysis.JMIR public health and surveillance · 2024Article
- Chinese parents' intention to vaccinate their 0-5-year-old children with the EV-71 vaccine against hand, foot, and mouth disease and willingness-to-pay.Frontiers in public health · 2024Article
- A guideline for economic evaluations of vaccines and immunization programs in China.Human vaccines & immunotherapeutics · 2022Article
- Spatial-temporal-demographic and virological changes of hand, foot and mouth disease incidence after vaccination in a vulnerable region of China.BMC public health · 2022Article
- Study on the interaction between different pathogens of Hand, foot and mouth disease in five regions of China.Frontiers in public health · 2022Article
- Spatiotemporal cluster patterns of hand, foot, and mouth disease at the province level in mainland China, 2011-2018.PloS one · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundIn China, enterovirus 71 (EV71) is the major etiological agents of hand foot mouth disease that poses severe risks to children's health. Since 2015, three inactivated EV71 vaccines have been approved for use. Previous studies indicated the high willingness of EV71 vaccination in eastern China. However, few studies have assessed coverage and utilization patterns of EV71 vaccine in China.
methodsChildren born during 2012-2018 were sampled and their records were abstracted from Ningbo childhood immunization information management system. Descriptive statistics characterized the study population and assessed coverage and timeliness for EV71 vaccination. Simultaneous administration patterns as well as type of EV71 vaccine used were also evaluated. Bivariate and multivariable analysis was used to examine the relationship of socio-demographic characteristics with vaccination coverage and timeliness.
resultsOf 716,178 children living in Ningbo. One hundred seventy-two thousand two hundred thirty-six received EV71 vaccine with a coverage rate of 24.05% and only 8.61% received vaccination timely. 21.97% of children received the complete two dose EV71 series but only 6.49% completed timely. Vaccination coverage and timeliness increased significantly from 2012 birth cohort to 2018 birth cohort. Relatively higher coverage and timeliness were observed in resident children, Inner districts, high socioeconomic areas and large-scaled immunization clinics. Of 329,569 doses of EV71 vaccine, only 5853(1.78%) doses were administered at the same day as other vaccines.
conclusionsThere is a need for increasing EV71 vaccination coverage and timeliness as well as eliminating disparities among different populations. Our study highlights the importance of simultaneous administration to increasing coverage and timeliness of EV71 vaccination.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.